Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30301279 | 1.00 | TRPV4 (0.37) | TRPV4TDP1L3MBTL1BCAT1NOTUM | |
| SCHEMBL25953713 | 0.84 | TRPV4 (0.38) | TRPV4TDP1L3MBTL1NOTUM | |
| SCHEMBL2729265 | 0.82 | TRPV4 (0.37) | TRPV4TDP1L3MBTL1NOTUM | |
| SCHEMBL29450561 | 0.82 | TRPV4 (0.37) | TRPV4TDP1L3MBTL1NOTUM | |
| SCHEMBL186689 | 0.80 | TRPV4 (0.42) | TRPV4BCAT1NOTUM | |
| SCHEMBL16122475 | 0.80 | TRPV4 (0.36) | TRPV4TDP1L3MBTL1BCAT1 | |
| SCHEMBL17929420 | 0.78 | AR (0.37) | TRPV4TDP1L3MBTL1 | |
| SCHEMBL29424964 | 0.78 | TDP1 (0.32) | TRPV4TDP1L3MBTL1 | |
| SCHEMBL22288637 | 0.78 | TDP1 (0.32) | TRPV4TDP1L3MBTL1 | |
| SCHEMBL27215201 | 0.78 | USP8 (0.35) | TRPV4TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115745974-A | Chiral near ultraviolet organic electroluminescent material, preparation method thereof and application thereof in CP-OLED | 华南理工大学 | 2023-03-07 | — | — | CN | claimed |
| EP-3654968-B1 | METALLO-BETA-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-3654968-B1 | METALLO-BETA-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2023056589-A1 | MENIN INHIBITORS AND METHODS OF USE FOR TREATING CANCER | SERVIER PHARMACEUTICALS LLC (US) | 2023-04-13 | — | — | WO | disclosed |
| CN-115745974-A | Chiral near ultraviolet organic electroluminescent material, preparation method thereof and application thereof in CP-OLED | 华南理工大学 | 2023-03-07 | — | — | CN | disclosed |
| US-11207312-B2 | Metallo-beta-lactamase inhibitors and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2021-12-28 | — | — | US | disclosed |
| US-20200375987-A1 | METALLO-BETA-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. (US) | 2020-12-03 | — | — | US | disclosed |
| EP-3735242-A1 | METALLO-BETA-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF | Merck Sharp&Dohme Corp. (US) | 2020-11-11 | — | — | EP | disclosed |
| US-20200281913-A1 | Metallo-Beta-Lactamase Inhibitors and Methods of Use Thereof | MERCK SHARP & DOHME CORP. (US) | 2020-09-10 | — | — | US | disclosed |
| US-10668071-B2 | (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-06-02 | — | — | US | disclosed |
| US-20170239251-A1 | (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-08-24 | — | — | US | disclosed |
| US-9598417-B2 | (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-03-21 | — | — | US | disclosed |
| US-9598417-B2 | (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-03-21 | — | — | US | disclosed |
| US-9598417-B2 | (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-03-21 | — | — | US | disclosed |
| EP-3066100-A1 | (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AS INHIBITORS OF FIBRINOLYSIS | Bayer Pharma Aktiengesellschaft (DE) | 2016-09-14 | — | — | EP | disclosed |
| WO-2015067549-A1 | (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AS INHIBITORS OF FIBRINOLYSIS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-05-14 | — | — | WO | disclosed |
| WO-2015067549-A1 | (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AS INHIBITORS OF FIBRINOLYSIS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-05-14 | — | — | WO | disclosed |
| US-20150126449-A1 | (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-05-07 | — | — | US | disclosed |
| US-20150126449-A1 | (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-05-07 | — | — | US | disclosed |
| US-20150126449-A1 | (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200281913-A1 | Metallo-Beta-Lactamase Inhibitors and Methods of Use Thereof | MLX, MMP12, SLC11A2 | TRPV4 4843/4885TDP1 3625/4885L3MBTL1 718/4885 |
| US-10668071-B2 | (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use | SERPINB6, SERPINC1, SERPINE1 | TRPV4 3626/4885TDP1 2457/4885L3MBTL1 3632/4885 |
| US-20200375987-A1 | METALLO-BETA-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF | SLC11A2, MMP12, LCT | TRPV4 4843/4885TDP1 3411/4885L3MBTL1 591/4885 |
| US-20150126449-A1 | (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use | SERPINB6, SERPINC1, SERPINE1 | TRPV4 3626/4885TDP1 2457/4885L3MBTL1 3632/4885 |
| US-20170239251-A1 | (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AND THEIR USE | SERPINB6, SERPINC1, SERPINE1 | TRPV4 3626/4885TDP1 2457/4885L3MBTL1 3632/4885 |
| US-11207312-B2 | Metallo-beta-lactamase inhibitors and methods of use thereof | MLX, MMP12, SLC11A2 | TRPV4 4843/4885TDP1 3625/4885L3MBTL1 718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.